Leslie Seiber

[Leslie Seiber @ljseiber]

Congratulations to the OBVIUS Team for successful “first in human” clinical cases!

[OBVIUS Robotics, Inc @Obviusrobotics]

OBVIUS Robotics Inc., a medical device company that has developed an innovative technology platform for performing percutaneous access, is proud to announce the first successful completion of human cases.

https://t.co/Xun9gA33yC

[Leslie Seiber @ljseiber]

⁦@DukeEnergy Please help me understand. Is this “imminent threat” or long term planning? Shocked to come home and see our 2-3 ft baby pines cut down located 10 ft away from the 90 ft power line overhead. ⁦@Asplundh_Tree⁩ #environmentallyfriendly
Is cleanup included?

[Leslie Seiber @ljseiber]

@p2simons Fortunately seems to prefer acorns….

[Leslie Seiber @ljseiber]

Gotta love the unexpected guest showing up on your doorstep for Sunday Brunch😳

[Heart Rhythm Society @HRSonline]

NEW #EPonEP: Do risk factor modifications for obstructive sleep apnea impact outcomes for #AFib patients? Find out with @EPrystowskyonEP and @drsuneet. #EPeeps #MedEd #CardioTwitter https://t.co/CxVSZB6lgq

[Leslie Seiber @ljseiber]

My very accomplished daughter is raising her’s to be a strong, independent young lady. Apparently working well based on her recent school assignment. Who has the nerve to tell her about the misspelling? ❤️😂

[Suneet Mittal @drsuneet]

Welcome on board @HughCalkinsMD!!! #iCLAS #ULTC

[Edward J Schloss MD @EJSMD]

.@drsuneet put on the spot by Hugh Calkins:

— aMAZE is done. What do you think it will show? Does LAA isolation work?
Defers, but says they are comfortable with the safety data and continue to enroll patients in the continued access trial.

#WAFib2021

[Adagio Medical @AdagioMedical]

Congratulations ⁦@AbdiRasekh⁩ on 1st enrollment in the iCLAS IDE Trial for persistent #AF. A pleasure to work with you and the stellar team ⁦@StLukesHealthTX⁩ ! ⁦@drsuneet⁩ ⁦@tomdepotter⁩

[Leslie Seiber @ljseiber]

Yes we are! @p2simons @raseiber1

[JK Han MD @netta_doc]

All are very much looking forward to the #aMAZEtrial results later this year! (Enrollment completed 12/2019)

#WAFib2021

[Edip Gurol @guroledip]

Let's RETWEET & submit questions to @guroledip - Topics: 1) @AFib_Disease detection 2) Left Atrial Appendage Closure 3) PFO Closure 4) New drugs/indications 5) @norocardiology syndromes. Cc @CMichaelGibson @DLBHATTMD @adnanalkhouli @SposatoL @ShadiYaghi2 @Jan_FriSch @DebbeMcCall

[Adagio Medical @AdagioMedical]

A true privilege for our team to learn from Dr. James Cox, a pioneer in the treatment of #AFib. Thank you Dr. Cox for sharing your expertise and passion for the advancement in care for #patients with atrial fibrillation! @NMCardioVasc

[Leslie Seiber @ljseiber]

@drsuneet @Jeep #WINNER

[Leslie Seiber @ljseiber]

Thank you Dr. Mittal for your leadership in this important trial studying safety and efficacy of the iCLAS cryoablation technology for patients with persistent #AFib!

[Adagio Medical @AdagioMedical]

Co-Lead Investigator of the IDE iCLAS Trial @drsuneet presents Early Clinical Results with the Ultra-Low Linear Cryoablation Catheter https://t.co/Woe65FHXHp via @YouTube #AtrialFibrillation @DrBradleyKnight #CastAF

[Adagio Medical @AdagioMedical]

⁦@tomdepotter⁩ presents clinical results with the Ultra-Low Temperature Continuous Lesion Ablation System. #AFSymposium2021
⁦@boersma_lucas⁩

[Leslie Seiber @ljseiber]

Thank you @DrBradleyKnight for your leadership on this initiative! A win-win

[Bradley Knight @DrBradleyKnight]

Published Ahead of Print! Editorial: Help Vaccinate EP Industry Representatives https://t.co/lxatG5DBOL

[Tolga Aksu, MD @MDTolgaAksu]

A free read in @JACCJournals Subxiphoid hybrid epicardial-endocardial ablation with LAA ligation was related to freedom from AT/AF 91% at 6 months, 90% at 12 months, 92% at 18 months, and 92% at 24 months in patients w per AF (87%) and LSPAF (13%) https://t.co/cSzJdJ95kP

[Adagio Medical @AdagioMedical]

A privilege to work with ⁦@tomdepotter⁩ & his excellent team ⁦⁦@OLVZaalst⁩. Their procedural efficiency is consistently impressive with the CE marked iCLAS catheter with a most recent persistent #AF procedure time of 49 minutes!

[Adagio Medical @AdagioMedical]

Congratulations ⁦@Drdevignair⁩ & ⁦@StBernards⁩ Team on first enrollments and cases in the iCLAS IDE Trial studying safety & efficacy of cryoablation technology. Thank you for your commitment to advancing care for patients with persistent #AFib!

[Adagio Medical @AdagioMedical]

Congratulations ⁦@Drdevignair⁩ on site activation in the iCLAS Trial using cryoablation technology to treat patients with persistent #AFib! Look forward to working with you & the ⁦@StBernards⁩ Team! ⁦@drsuneet⁩ ⁦@tomdepotter⁩